Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial

PURPOSE: This study estimated time without symptoms or toxicity (TWiST) with niraparib compared with routine surveillance (RS) in the maintenance treatment of patients with recurrent ovarian cancer. PATIENTS AND METHODS: Mean progression-free survival (PFS) was estimated for niraparib and RS by fitt...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Matulonis, Ursula A., Walder, Lydia, Nøttrup, Trine J., Bessette, Paul, Mahner, Sven, Gil-Martin, Marta, Kalbacher, Elsa, Ledermann, Jonathan A., Wenham, Robert M., Woie, Kathrine, Lau, Susie, Marmé, Frederik, Casado Herraez, Antonio, Hardy-Bessard, Anne-Claire, Banerjee, Susana, Lindahl, Gabriel, Benigno, Benedict, Buscema, Joseph, Travers, Karin, Guy, Holly, Mirza, Mansoor R.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2019
Matèries:
RAPID COMMUNICATIONS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6881097/
https://ncbi.nlm.nih.gov/pubmed/31518175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00917
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars